Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2001-7-4
pubmed:abstractText
This report concerns a clinical trial for rheumatoid arthritis (RA), approved by the US National Institutes of Health and the Food and Drug Administration. An amphotropic retrovirus (MFG-IRAP) was used ex vivo to transfer a cDNA encoding human interleukin-1 receptor antagonist (IL-1Ra) to synovium. The protocol required the transduced cells to secrete at least 30 ng IL-1Ra/10(6) cells per 48 h before reimplantation. Here we have evaluated various protocols for their efficiency in transducing cultures of human rheumatoid synoviocytes. The most reliably efficient methods used high titer retrovirus (approximately 10(8) infectious particles/ml). Transduction efficiency was increased further by exposing the cells to virus under flow-through conditions. The use of dioctadecylamidoglycylspermine (DOGS) as a polycation instead of Polybrene (hexadimethrine bromide) provided an additional small increment in efficiency. Under normal conditions of static transduction, standard titer, clinical grade retrovirus (approximately 5 x 10(5) infectious particles/ml) failed to achieve the expression levels required by the clinical trial. However, the shortfall could be remedied by increasing the time of transduction under static conditions, transducing under flow-through conditions, or transducing during centrifugation.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/11438045-10755210, http://linkedlifedata.com/resource/pubmed/commentcorrection/11438045-1567555, http://linkedlifedata.com/resource/pubmed/commentcorrection/11438045-2846503, http://linkedlifedata.com/resource/pubmed/commentcorrection/11438045-3413107, http://linkedlifedata.com/resource/pubmed/commentcorrection/11438045-7474118, http://linkedlifedata.com/resource/pubmed/commentcorrection/11438045-8248169, http://linkedlifedata.com/resource/pubmed/commentcorrection/11438045-8379462, http://linkedlifedata.com/resource/pubmed/commentcorrection/11438045-8530565, http://linkedlifedata.com/resource/pubmed/commentcorrection/11438045-8552648, http://linkedlifedata.com/resource/pubmed/commentcorrection/11438045-8617986, http://linkedlifedata.com/resource/pubmed/commentcorrection/11438045-8793551, http://linkedlifedata.com/resource/pubmed/commentcorrection/11438045-8919596, http://linkedlifedata.com/resource/pubmed/commentcorrection/11438045-9153551, http://linkedlifedata.com/resource/pubmed/commentcorrection/11438045-9920008, http://linkedlifedata.com/resource/pubmed/commentcorrection/11438045-9930318
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1465-9905
pubmed:author
pubmed:issnType
Print
pubmed:volume
3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
259-63
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2001
pubmed:articleTitle
Approaches to enhancing the retroviral transduction of human synoviocytes.
pubmed:affiliation
Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, PA, USA. cevans@rics.bwh.harvard.edu
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Research Support, U.S. Gov't, P.H.S., Evaluation Studies